Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 22, 2006

View Archived Issues

Combined intravenous/intraarterial rt-PA assessed in ischemic stroke patients

Piracetam protects against cognitive impairment after coronary artery bypass grafting

Encouraging phase I results for rotavirus vaccines

MDS Nordion to supply Zemiva to Molecular Insight Pharmaceuticals

King and Arrow collaborate on new formulations of Altace

Diversa and BASF establish broad alliance to develop new products

Targeted CCR5 gene disruption renders human primary cells resistant to HIV

Novel class of allosteric Bcr-Abl inhibitor that potentiates imatinib

Nitrite infiltrations provide neuroprotective benefits in brain ischemia

Antitumor effects of targeting thioredoxin

Numerous agents under investigation in pancreatic and hepatic cancer

BCY and Pipex complete business combination discussions

CSL reports encouraging results from Australian pandemic influenza vaccine trial

Kyorin signs license agreement with Novartis for immunomodulator KRP-203

U.S. BioDefense validates human neural crest stem cells

Fispemifene begins phase II trial to treat symptoms of andropause

Dosing begins in phase III study of ospemifene for vaginal atrophy

Planned Oxycyte phase II trial placed on hold for protocol revisions

Recruitment interrupted in phase III trial of Neovastat in NSCLC

Bristol-Myers Squibb strengthens Tequin warnings

Relenza approved for children aged five or older in Japan

Novel agents for treating neurological disorders disclosed in recent patent literature

U.S. launch of Ultram ER

Eraxis approved to treat candidemia

Sweden approves Multiferon in malignant melanoma

Recent Roche patent reports novel therapeutics for HIV infection

Recent patents reveal novel antidiabetic agents

The antipsychotic drug trifluoperazine may be useful to prevent opioid tolerance

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...